Determination of ajulemic acid and its glucuronide in human plasma by gas chromatography-mass spectrometry.

Author(s): Batista C, Berisha M, Karst M, Salim K, Schneider U, Brenneisen R

Affiliation(s): Laboratory for Phytopharmacology, Bioanalytics and Pharmacokinetics, Department of Clinical Research, University of Bern, Murtenstrasse 35, CH-3010 Bern, Switzerland.

Publication date & source: 2005-06-05, J Chromatogr B Analyt Technol Biomed Life Sci., 820(1):77-82. Epub 2005 Apr 12.

Publication type: Clinical Trial; Randomized Controlled Trial; Validation Studies

A method using gas chromatography-mass spectrometry (GC-MS) and solid-phase extraction (SPE) was developed for the determination of ajulemic acid (AJA), a non-psychoactive synthetic cannabinoid with interesting therapeutic potential, in human plasma. When using two calibration graphs, the assay linearity ranged from 10 to 750 ng/ml, and 750 to 3000 ng/ml AJA. The intra- and inter-day precision (R.S.D., %), assessed across the linear ranges of the assay, was between 1.5 and 7.0, and 3.6 and 7.9, respectively. The limit of quantitation (LOQ) was 10 ng/ml. The amount of AJA glucuronide was determined by calculating the difference in the AJA concentration before ("free AJA") and after enzymatic hydrolysis ("total AJA"). The present method was used within a clinical study on 21 patients suffering from neuropathic pain with hyperalgesia and allodynia. For example, plasma levels of 599.4+/-37.2 ng/ml (mean+/-R.S.D., n=9) AJA were obtained for samples taken 2 h after the administration of an oral dose of 20 mg AJA. The mean AJA glucuronide concentration at 2h was 63.8+/-127.9 ng/ml.